The time of progression towards AIDS can vary greatly among seropositive patients, ranging from as little as three to as long as 20 years after infection. Previous studies estimated that 10% of HIV positive patients develop AIDS within two to three years (rapid progressors), and 5-15% will remain AIDS-free after 20 years (slow progressors) ([@B3]). Several attempts to explain differential progression towards AIDS have been made, and so far multiple genes have been shown to play a role in shaping individual time of progression, affecting susceptibility, transmission, and course of disease, ultimately determining viral set points, rate of decline of CD4+ T-cells, level of viremia and cytotoxic T lymphocytes escape ([@B12]). The extent to which each of those genes influences AIDS onset is not clear, but it is understood to be the result of multiple small factors combined. Nuclear receptors (NR), a family of transcription factors (TF) which comprise the so called orphan receptors, are among the host factors currently known to have some influence in AIDS progression ([@B8]. [@B9] and his team have shown two specific NRs that play an import role in diminishing HIV replication through specific mechanisms in vitro. The *NR1I2* (PXR) gene, ligand-activated TFs, regulate the transcription of a wide range of genes ([@B30], [@B28], including immune pathways ([@B15] and can therefore be targets of viral replication mechanisms influencing time of progression to AIDS. The *NR1I2* (PXR) is also a key to gene regulation, influencing morphogenesis and differentiation, and it may also play a role in the cell cycle progression ([@B24], [@B31]. Currently available studies also indicate that PXR regulates CYP3A4 expression ([@B28], which is involved in the metabolism of antiretrovirals and therefore could be a key predictor of drug responsiveness and toxicity ([@B23], [@B25], [@B6]. This study aims to investigate an association of polymorphisms in the PXR gene with time of progression to AIDS.

MATERIALS AND METHODS
=====================

*Study sample* - Ninety-six blood samples were obtained from HIV-positive patients following stringent review of 3500 medical charts between 2011-2013 in the hospital located in Porto Alegre city, Southernmost Brazil.

For these patients, it was possible to clearly determine the time of progression for AIDS, considering the middle time between HIV-negative and HIV-positive serology, using the retrospective data of their medical records. It is important to note that this parameter is in accordance with the prevailing Brazilian guidelines for the management of HIV+ patients in the country affective in 2013. The Ministry of Health Guidelines for Antiretroviral Treatment indicates that the initiation of Highly Active Antiretroviral Therapy (HAART) should occur for both symptomatic and asymptomatic HIV-1 patients with CD4+ T-cell counts below 350 cells/mm3 and/or a persistently high viral load ([@B19]).

Data available in the medical records, such as the date of seroconversion, HIV-negative serology date, HIV-positive serology date, date of antiretroviral treatment initiation, and lymphocyte count CD4+, were used to classify patients according to the following criteria: (i) rapid progressors, the period from seroconversion (considering middle time between HIV-negative and HIV-positive serology) to the beginning of treatment for AIDS of up to three years, with at least two consecutive CD4+ counts \< 350 cells/mm^3^ before data collection and HAART medical recommendation; (ii) typical progressors, the period from HIV-positive serology (with clinical monitoring) to the treatment for AIDS of over four years, with at least three consecutive CD4+ T lymphocytes counts \> 500 cells/mm^3^ before data collection and HAART medical recommendation; (iii) slow progressors, the period from HIV-positive serology exceeding nine years, with CD4+ T lymphocytes counts \> 500 cells/mm^3^ and without requiring treatment for AIDS. The analyses were performed using this classification in rapid, chronic, and slow progressors.

Other data concerning the individual features of patients were obtained through a sociodemographic questionnaire. The individuals were classified as of European or African ancestry, according to the phenotypic characteristics of individuals, as judged by the researcher at the time of data collection, and from data about the ethnicity of the parents/grandparents reported by the participants. According to [@B21], the Brazil Southernmost Region showed reduced mixing compared to the rest of the country, due to great geographical variances and cultural differences in the country. The issue concerning the skin-color-based classification criteria used in this geographical area of Brazil is well documented and has already been assessed in previous studies ([@B7]).

*DNA extraction and genotyping* - Total DNA extraction from blood samples collected was performed through the well-established technique of salting out described by [@B14]. Genotyping of four single nucleotide polymorphisms (SNPs) in the *NR1I2* gene rs3814057 (A \> C; mRNA 3'UTR), rs6785049 (G \> A; intronic region), rs7643645 (A \> G; intronic region), and rs2461817 (A \> C; intronic region), were performed by real time polymerase chain reaction (PCR) and validated by TaqMan assays (Applied Biosystems, California, USA). The SNPs evaluated here were selected using the HapMap tool (www.hapmap.org) with the following annotate TagSNP Picker features: European population (CEU), minimum frequency of the rarest allele of 10% and a determination coefficient (R^2^) equal to 80%. *HLA-B\*27*, and *HLA-B\*57* and *CCR5del32* genotypes were available for the sample and used to control for known genetic factors involved in the progression to AIDS. The *CCR5del32* (rs333) variant was previously evaluated by PCR and visualised on 3% agarose gel, as described by [@B5]. The presence of *HLA-B\*27* and *HLA-B\*57* were previously genotyped according [@B4].

*Statistical analysis* - Categorical variables are described in proportions and continuous variables and are expressed as the mean \[standard deviation (SD)\] or median \[interquartile range (IQR)\]. Allelic frequencies were estimated through gene counting. The agreement of genotype frequencies with Hardy-Weinberg equilibrium expectations was tested using Chi-square tests.

Initially, patients enrolled were grouped as rapid, chronic, and slow progressors according to the data obtained from the questionnaire and review of the subjects' medical charts. Their CD4+ T-cell slope values before HAART were estimated by linear regression with the square root of the CD4+ T-cell count and a non-parametric Mann-Whitney and exact Fisher test were used to characterise the progression of the patients according socio-demographic characteristics of patients. After characterisation of the sample, all variables were tested using Cox regression in a univariate model. Multivariate Cox regression was performed considering a forward stepwise model and all three models with statistical significance are shown on results. Genetic recessive models for *NR1I2* polymorphisms were assumed. All statistical analyses were performed with IBM SPSS Statistics for Windows, version 19.0 (IBM Corp, Armonk, NY) and p \< 0.05 was considered to indicate statistical significance.

*Ethics* - The study protocol was approved by the Ethical Committees of the Conceição Hospital Group (Porto Alegre) (approval number 10-213) and Fundação Estadual de Produção e Pesquisa (FEPPS) (approval number 13/2010). Written informed consent was obtained from each subject included in the study.

RESULTS
=======

*Characteristics of study population* - [Table I](#t1){ref-type="table"} contains data regarding sample description and comparison of clinical and socio-demographic variables between slow, typical, and rapid progressors. Female sex was slightly more frequently observed among slow and typical progressors than in rapid progressors (p = 0.067). Characterisation of disease progression included significant differences (p \< 0.001) in the values of CD4+ T-cells slopes: the number of CD4+ T-cells decreased more abruptly in rapid progressors (median slope -0.988; IQR -2.424 to -0.399) and typical progressors (median slope -1.090; IQR -2.649 to -0.427) than in the slow progressors (median slope -0.473; IQR -0.881 to -0.160). Twenty-three patients in the slow group did not start antiretroviral therapy at the time of study completion (follow-up median = 9.75 years; IQR = 8.25-12.25 years).

TABLE ISocio-demographic and clinical features of study sampleVariableTotal (96)Type of progressionp valueRapid (20)Typical (40)Slow (36)Time to AIDS (years)7.0 (1-15)1.55(1-3)5.89(4-8)11.21(9-15)\< 0.001Slope CD4+ (cell/mm^3^)\--0.988 (-2.424; -0.399)-1.090 (-2.649; -0.427)-0.473 (-0.881; -0.160)\< 0.001Female75.0%55.0%80.0%80.5%0.067Age (years)40.81(10.21)42.72 (11.06)40.07 (11.83)40.52 (8.43)0.640Transmission     Het76.0%75.0%80.0%72.2%0.725MSM8.3%15.0%7.5%5.5%0.458IDU8.3%5.0%5.0%14.0%0.312Others6.3%5.0%5.0%8.3%0.808Ethnicity     White58.3%57.9%74.3%45.0%0.025Non-white41.7%42.1%25.7%55.0% Co-infection (yes)38.5%55.0%37.1%31.8%0.194[^2]

*Association of NR1I2 gene polymorphisms and time of progression to AIDS* - [Table II](#t2){ref-type="table"} shows the comparison of *NR1I2* SNPs among rapid, typical, and slow progressors. Although no association was detected for any SNP, an association with the rs7643645 GG genotype was observed when the comparison of rapid plus typical versus slow progressors was performed (p = 0.0216). Considering that sex \[hazard ratio (HR) = 1.608, confidence interval (CI)95% 1.000-2.587, p = 0.050\] and ethnicity (HR = 1.657, CI95% 1.054-2.606, p = 0.029) showed significance in Cox Regression Univariate test ([Table III](#t3){ref-type="table"}), and that *HLA-B\*57*, *HLA-B\*27,* and *CCR5 del32* polymorphisms are well known factors that affect time to progress to AIDS, a multivariate stepwise Cox regression was performed. In this analysis, three models were generated. In model three (step 3 on [Table III](#t3){ref-type="table"}) our results evidenced an association of rs7643645 GG genotype to a shorter time of progression (HR = 2.029, CI95% 1.036-3.975, p = 0.039) when compared to GA and AA genotypes ([Table III](#t3){ref-type="table"}). No other polymorphisms were significantly associated with time of progression towards AIDS.

TABLE IIGenotypic distribution of *NRI1I2* single nucleotide polymorphisms (SNPs) among rapid, typical, and slow progressorsSNPType of progressionp valueRapidTypicalSlowrs2461817AA4 (21.1%)7 (17.9%)3 (10.7%) AC10 (52.6%)19 (48.8%)15 (53.7%)0.866CC5 (26.3%)13 (33.3%)10 (35.6%) rs3814057AA7 (35.0%)16 (40.0%)15 (51.8%) AG11 (55.0%)20 (50.0%)11 (37.9%)0.781GG2 (10.0%)4 (10.0%)3 (10.3%) rs6785049AA1 (5.0%)8 (20.5%)8 (27.6%) AG13 (65.0%)18 (46.2%)12 (41.4%)0.321GG6 (30.0%)13 (33.3%)9 (31.0%) rs7643645\*AA8 (40.0%)14 (35.0%)17 (58.6%) AG10 (50.0%)18 (45.0%)12 (41.4%)0.077\*GG2 (10.0%)8 (20.0%)0 (0%) [^3]

TABLE IIIUnivariate and multivariate Cox proportional hazards regression analysis concerning rs7643645 SNP and risk for progression to AIDS Univariate analysisHR95%CIp valueSex (male)1.6081.0002.5870.050Ethnicity (white)1.6571.0542.6060.029G homozygosis1.8100.9153.7890.083CCR5del320.7920.3521.7420.588HLA-B\*57/B\*270.9480.4522.1890.803  Forward stepwise multivariate analysis HR95%CIp value*Step 1*\*Ethnicity (white)1.6311.0412.7890.037*Step 2* \*\*Sex (male)1.7361.0532.9150.028Ethnicity (white)1.7101.1362.8030.021*Step 3* \*\*\*Sex (male)1.9451.1613.2580.011Ethnicity (white)1.7101.0032.6140.049G homozygosis2.0291.0363.9750.039[^4]

DISCUSSION
==========

This study evaluated the possible influence of four common SNPs from *NR1I2* gene in the time of progression to AIDS. The major finding of this study was the significant association of the rs7643645 polymorphism, gender, and ethnicity with a shorter time of progression towards AIDS. In the rs7643645 polymorphism, the genotype GG has a major risk to progression for disease.

The characterisation of AIDS progression is diverse in literature ([@B12], [@B3], and presence of AIDS symptoms, CD4+ T-cell counts and plasma HIV RNA levels already were considered by different authors to classify the AIDS progression ([@B18], [@B20]. This study used retrospective CD4+ T-cell counts to assess the progression to AIDS, so initially the patients' progression was validated by the significant difference in the slope of decline in CD4+ T-cell numbers between rapid progressors (-0.988, steep slope) and slow progressors (-0.473, gentle slope).

The analysis on the socio-demographic features of patients showed a positive association between female gender and slow progression to AIDS (p-value = 0.019). This finding is in agreement with other studies, which found higher CD4+ TL counts in females than in male HIV-patients ([@B11]). However, a recent study by [@B27] found no association between sex and onset of AIDS. It is important to also consider the influence of the patient's selection mode to reach our results. Patients enrolled were those who voluntarily sought health care, which can constitute a bias, since usually in Brazil more women look for health care services than men ([@B22]) and our collection site (Conceição Hospital Group) has specific health service for pregnant women. Moreover, a positive association between non-white individuals and slow progression to AIDS was also encountered (p-value = 0.053). [@B20] showed an increased frequency of African-American individuals among long-term non-progressors in a USA cohort. Further, an earlier study of [@B1] had observed an association between slower decline in CD4+ TL and non-white individuals. Despite of the small sample size investigated due the limited data about progression to AIDS and the ethnic composition of Brazilian population, the results show that investigations including populations of different ancestries and geographic regions are important to understand how genetic background can influence immune responses and modulate HIV infection and progression. HIV affects the entire immune system of the patient, so the pathways and genes studied are those associated with the immune system. However, it is increasingly recognised that gene regulation should be mediated, for example, for nuclear transcription factors such as PXR family receptors encoded by *NR1I2*. These receptors form a network, which influences the expression of many other genes. These interactions are complex and may be simulated using function prediction analysis tools made with an online tool (available at http://snpinfo.niehs.nih.gov). The interactions of *NR1I2* involve tumor suppressor genes, cell cycle regulators and differentiation, inflammatory response promoters, genes involved in production of blood cells and the response of cells to retroviral infection. A recent study demonstrated that PXR expression on peripheral blood cells is different in tissue expression, and this variable in combination with other markers can modulate the immune response of human body to the tumor cells. Following this reasoning, considering that the receptor PXR is able to modulate the recognition of abnormal cells, it is questionable and important to study its real relevance in cells infected with HIV ([@B13]).

The findings in this study regarding the association of allele G homozygosis in rs7643645 and a rapid progression to AIDS are in agreement with [@B24], who suggested an apparent role for PXR in immune response. In that study, it was observed that PXRs, among others NRs, are expressed in CD4+ TL, CD8+ TL, CD14+ TL and CD19+ TL, which suggests their function influences expression of molecules involved in immune mechanisms. The mechanism through which PXR correlates to AIDS progression is not all unraveled to date. However, it is known that it is related to the metabolism of the drugs used to treat AIDS patients, given its role in Phase I and II metabolism of xenobiotics and also being suppressed by some drugs. These studies relate the amount of antiretroviral drugs available in the plasma of patients with polymorphisms in *NR1I2* and *NR1I3*, and consequently the resistance to drugs and prognosis of these patients ([@B10], [@B26]).

It is known, though, that metabolism and inflammation are related mechanisms. In the presence of cytokines and of a specific types of inflammation (acute phase response by lipopolysaccharide), for instance, a decreased expression of PXR and of its target genes is seen ([@B17]). It has been suggested that a relationship between PXR and NFkappa-beta functions exists, with NF-kb increased action in PXR null mice as well as a decrease of PXR function with inhibition of NF-kbs, demonstrating a potential for immunosuppressive activity of PXR's ligands ([@B29]). This leads to the belief of a possible influence of this NR in the course of immunosuppressive diseases, such as AIDS, as we have found.

Our study presents some limitations and the results must be interpreted considering some issues: (i) we analyse a small sample of HIV+ patients due the limited data about progression to AIDS; (ii) we genotype a small number of polymorphisms and other *NR1I2* SNPs could be associated with the progression to AIDS; (iii) our data do not represent the actual distribution of slow, typical and rapid progressors in HIV + patients, since a high frequency of slow progressors is observed in the sample; (iv) a group of patients who had not started antiretroviral therapy at the time of inclusion in the study was classified as slow progressor. This group was not fully characterised and potentially includes LTNPs patients (long-term non-progressors patients). Despite this, this is the first time that a *NR1I2* gene polymorphism was found to be related to time of progression to AIDS and even though our sample was not an extensive representative, it can be hypothesized that the absence of the rs7643645 SNP in homozygosis (presence of the A allele) is associated with a delayed progression towards AIDS, when also considering ethnicity and gender. This agrees with the widely accepted belief of several different factors influencing AIDS progression and illustrates the importance of considering them all together ([@B16]). In addition, this finding is in accordance to several recent studies that suggest a role of NR in immune mechanisms and HIV infection. The presented results support the evidence and stress the importance of continuation of the search for additional genes' activities that might be related to the development of this widespread disease. It also claims for the elucidation of mechanisms through which it occurs and investigation of other NRs in the matter.
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